Please assess the completion status of the following clinical trial:

Trial Title: Dose Individualization of Pemetrexed - IMPROVE-II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥18 years old~2. Eligible for treatment with pemetrexed-based chemotherapy~3. Creatinine clearance \>45ml/min~4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2~5. Subject is able and willing to sign the Informed Consent Form~Exclusion Criteria:~1. Conditions that affect haemostasis in a way that blood drawing is complicated (to be assessed by physician)~2. Contraindications for treatment with pemetrexed in line with the summary of product characteristics (SmPC) (except for creatinine clearance \<45 ml/min in IMPROVE-I)~   1. Hypersensitivity to the active substance or to any of the excipients~  2. Pregnancy or lactation~  3. Concomitant yellow fever vaccine~3. The presence of clinically relevant pharmacokinetic interactions, according to the current SmPC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (BSA-based dosing) (Type: ACTIVE_COMPARATOR): Dosing of pemetrexed is based on BSA according drug label
- Arm B (renal function based dosing) (Type: EXPERIMENTAL): Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.

Based on this trial design, predict the completion outcome and termination type (if applicable).